#### Indiana Health Coverage Programs



#### PROVIDER BULLETIN

BT200246

AUGUST 26, 2002

To: All Pharmacy Providers and Practitioners Prescribing

and Dispensing Medications

**Subject: ACS and HCE Prior Authorization Process** 

# **Overview and Background**

As stated in prior bulletins (*BT200235*, dated July 8, 2002, and *BT200243*, dated August 8, 2002), an Indiana Medicaid Preferred Drug List (PDL) is being implemented effective August 21, 2002, with non-sedating antihistamines being the first class included on the list. Proton pump inhibitors (PPIs) and ACE inhibitors are subjected to the PDL effective September 17, 2002.

All non-sedating antihistamines, PPIs, and ACE inhibitors *except the ones included on the PDL* will require prior authorization (PA) from ACS State Healthcare at 1-866-879-0106 toll free. Please note that since the Cox II inhibitors did not have a preferred drug added to the PDL, they will remain subject to the Indiana Rational Drug Program (IRDP) as is currently the case (provider bulletin *BT200148*) and, as such, require PA from Health Care Excel (HCE). Phone numbers for HCE are (317) 347-4511 in the Indianapolis local area, or 1-800-457-4518 toll free.

As additional categories of drugs are reviewed by the Therapeutics Committee and PDL status determination is subsequently made by the Drug Utilization Review (DUR) Board, providers will be given 30 days advance notice of additions to the PDL. Notice of meetings of the DUR Board and agendas for the meetings are posted in accordance with public notice requirements on the FSSA Web site, <a href="http://www.state.in.us/fssa/">http://www.state.in.us/fssa/</a>, under the heading Calendar and News. Additional information regarding the Therapeutics Committee and the PDL may be accessed at <a href="http://www.indianapbm.com/">http://www.indianapbm.com/</a>. Please also note that additional information regarding the PDL and related processes will be provided in the near future via banner page messages or bulletins.

The summary of ACS and HCE PA Process and POS Edit Codes is listed on page 3 of this bulletin.

# Therapeutic Consultation Program and PDL

Effective August 21, 2002, the PDL encompasses Indiana's clinical initiative, the Therapeutic Consultation Program (TCP). TCP is an in-bound call center in which *prescribers* call to review the member's profile for all non-preferred drugs with a TCP clinical pharmacist.

#### **ACS and HCE Prior Authorization Process**

# Non-Preferred Drugs

All non-preferred drug claims will deny and post Edit 3017 at the pharmacy POS. Pharmacy providers should inform the prescriber to call the ACS State Healthcare at 1-866-879-0106 to review the non-preferred drug with a TCP pharmacist.

#### Preferred Drug, Exceeding Maximum Quantity Limitation

All preferred drug claims exceeding the maximum quantity limitation will deny and post Edit 3017 at the pharmacy POS. Pharmacy providers should inform the prescriber to call the ACS State Healthcare at 1-866-879-0106 to review exceeding the maximum quantity limitation with a TCP pharmacist.

## **Brand Medically Necessary**

All drug claims associated with the PDL requiring brand medically necessary (BMN) will deny and post Edit 3017 at the pharmacy POS. Pharmacy providers should inform the prescriber to call ACS State Healthcare at 1-866-879-0106 for PA. If the drug requiring a BMN PA is also a non-preferred drug, two PAs will be needed to process the claim correctly: one PA for non-preferred and another PA for BMN. ACS will provide both PA for non-PDL and BMN for the non-preferred drug when requested together.

All drug claims **not** associated with the PDL requiring BMN will deny and post Edit 3002 at the pharmacy POS. Providers should call HCE at (317) 347-4511 in the Indianapolis local area or 1-800-457-4518 for PA.

## 34-Day Supply Limit for Non-Maintenance Medications

All non-maintenance drug claims associated with the PDL requiring quantities greater than a 34-day supply will deny and post Edit 3017 and Edit 4026 at the pharmacy POS. Pharmacy providers should inform the prescriber to call the ACS State Healthcare at 1-866-879-0106 for PA. As with BMN, two distinct PAs will be required for claim approval, one for the PDL and one for the 34 day supply limitation. PA will not be granted unless an extenuating circumstance exists to substantiate the need to dispense greater than a 34-day supply of the product.

All non-maintenance drug claims **not** associated with the PDL requiring quantities greater than a 34-day supply will deny and post Edit 4026 at the pharmacy POS. Providers should call HCE at (317) 347-4511 in the Indianapolis local area or 1-800-457-4518 for PA. Prior authorization will not be granted unless an extenuating circumstance exists to substantiate the need to dispense greater than 34-days supply of the product.

All IRDP therapy exceeding limitation will deny and post 6806 at the pharmacy POS. Providers should call HCE at (317) 347-4511 in the Indianapolis local area or 1-800-457-4518 for PA.

## Prospective Drug Utilization Review Alerts (ProDUR)

All ProDUR PA requests (Early Refill Edit 0570, High Dose Edit 0571, Therapeutic Duplication Edit 0572, Drug/Drug Interaction Edit 0573) should be referred to HCE at (317) 347-4511 in the Indianapolis local area or 1-800-457-4518.

#### **Emergency Supply**

In instances where PA cannot be immediately obtained, a pharmacist may dispense a 72-hour supply of a covered prescription drug and will be reimbursed by the IHCP if, subsequent to dispensing in an emergent situation, indication is made on the claim that the supply is for an emergency need.

#### **Edit 3017** PDL/Non-preferred drugs Call ACS 1-866-879-0106 BMN associated with PDL **Edit 3002 IRDP** Call HCE (317) 347-4511 1-800-457-4518 Edit 4026 Call HCE (317) 347-4511 NDC/ Days Supply Limitation 1-800-457-4518 Edit 0570 Refill too soon Call HCE (317) 347-4511 1-800-457-4518 Edit 6806 **IRDP** Call HCE (317) 347-4511 Therapy exceeds limitation 1-800-457-4518

#### POS Edit Codes

We hope and anticipate that prescribers and pharmacists will support and encourage the use of the PDL as it is implemented and further developed; and recognize and appreciate the clinical and cost effectiveness that it will bring to the Indiana Medicaid pharmacy benefit. Please bear in mind that the cost savings to be realized from the PDL approach will enable the OMPP to provide for the funding of other critically needed services under Medicaid, at a time when every possible means of conserving program costs is being explored.

- Please direct any questions that you have regarding this bulletin to EDS Customer Assistance at (317) 655-3240 in the Indianapolis local area or 1-800-577-1278.
- Please direct any questions about IRDP PA to HCE PA Department at (317) 347-4511, in the Indianapolis local area, or 1-800-457-4518.
- Please direct any questions about the PDL and PA needed for non-PDL drugs to ACS State Health Care at 1-866-879-0106.

CDT-3/2000 (including procedure codes, definitions (descriptions) and other data) is copyrighted by the American Dental Association.© 1999 American Dental Association. All rights reserved. Applicable Federal Acquisition Regulation System/Department of Defense Acquisition Regulation System (FARS/DFARS) Apply.

CPT codes, descriptions and other data only are copyright 1999 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Apply.